Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2022-05-23 00:00:00 ET · period of report 2022-05-19 · accession 0001209191-22-031508 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-23 | 2022-05-19 | QNCX | Smith Karen L. | Chief Medical Off | A - Grant | — | +24.3K | 24.3K | New | — |
| DM | 2022-05-23 | 2022-05-19+ | QNCX | Smith Karen L. | Chief Medical Off | A - Grant | $0.00 | +1.52M | 151.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-19 | A | A | 24,336 | — | 24,336 | D | — | — | (F1) On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2022-05-23 | A | A | 1,365,449 | $0.00 | 1,365,449 | D | $2.98 · — to 2032-05-22 | 1,365,449 Common Stock | (F2) The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2022-05-19 | A | A | 151,799 | — | 151,799 | D | $0.55 · — to 2032-03-27 | 151,799 Common Stock | (F3) Received in the Merger in exchange for an employee stock option to acquire 1,667,000 shares of Novosteo common stock for $0.05 per share. (F2) The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. |